Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Stopped early · Phase 2
Conditions studied: Refractory Plasma Cell Myeloma
In brief
This phase II trial studies how well giving bortezomib, lenalidomide, and dexamethasone together works in treating patients with multiple myeloma undergoing stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib, lenalidomide, and dexamethasone together may kill more cancer cells.
Key facts
- Study ID
- NCT02353468
- Run by
- University of Colorado, Denver
- People needed
- 3
- Starts
- 2009-12-01
- Expected to finish
- 2011-10-01
- Last updated by the study team
- 2015-03-09
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with symptomatic active multiple myeloma who have completed autotransplant are eligible for the study; patients should be assessed for eligibility within 35 days of the transplant and treatment should commence within 10 weeks of the transplant
- Performance status of 0-2 based on Southwest Oncology Group (SWOG) criteria; patients with a poor performance status (3-4) are also eligible, if complications of the bone such as compression fracture, hyperviscosity or infection such as pneumonia have been adequately treated
- No significant co-morbid medical conditions; no uncontrolled life threatening infection
- Unsupported platelet count > 80,000/uL
- Absolute neutrophil count (ANC) > 1000/uL
- Signed informed consent should be obtained from all patients in accordance with institutional and federal guidelines
You may not qualify if…
- Patients with a history of recent (< 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, difficult to control significant cardiac arrhythmias, or arrhythmia associated with prolonged QT interval
- Pregnant or nursing women; women of child-bearing potential must have a negative pregnancy documented within one week of registration; women/men of reproductive potential may not participate unless they have agreed to use two forms of effective contraceptive method
- Patients with a grade 3-4 neuropathy related to prior exposure to bortezomib, thalidomide, or other agents
- Human immunodeficiency virus (HIV) positive patients
- Transaminases > 2 x normal values
- Bilirubin > 2 x normal values
- Active uncontrolled infection
- History of significant psychiatric illness; steroid induced psychosis
Where it is running
- University of Colorado — Aurora, Colorado, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.